Company news
Innovation Pharmaceuticals Inc. news in 2021
Innovation Pharmaceuticals Inc.'s news releases, calls and decks from 2021, newest first.
Innovation Pharmaceuticals Analyzing Full Dataset for Its Brilacidin COVID-19 Clinical Trial; Company Evaluating New Pipeline Opportunities for 2022
December 6, 2021
Innovation Pharmaceuticals Provides Brilacidin Program Update
November 17, 2021
Innovation Pharmaceuticals Conducting Full Data Analysis of Phase 2 Brilacidin COVID-19 Trial Results to Support Brilacidin's Potential Inclusion in Government-Sponsored COVID-19 Trials
November 11, 2021
Innovation Pharmaceuticals Announces Topline Results from Phase 2 Clinical Trial of Brilacidin for COVID-19
November 10, 2021
Database Lock Completed for Innovation Pharmaceuticals' Phase 2 Clinical Trial of Brilacidin for COVID-19
November 2, 2021
Innovation Pharmaceuticals' COVID-19 Clinical Trial Topline Results Anticipated to Be Reported the Week of November 8th
October 24, 2021
Innovation Pharmaceuticals Provides Update on COVID-19 Clinical Trial, Compassionate Use Requests and Research into Brilacidin's Broad-Spectrum Antiviral Properties
September 22, 2021
Last Patient Last Visit Completed in Innovation Pharmaceuticals’ Phase 2 Clinical Trial of Brilacidin for COVID-19; Trial Database Undergoing Review in Preparation for Database Lock
August 12, 2021
Innovation Pharmaceuticals Provides Update on Brilacidin Antiviral Research
August 2, 2021
Innovation Pharmaceuticals Announces New In Vitro Data Supporting Brilacidin’s Broad-Spectrum Antiviral Potential Presented at the American Society of Virology’s Annual Meeting
July 22, 2021
Innovation Pharma Announces New Brilacidin Antiviral Research on Non-SARS-CoV-2 Endemic Viral Diseases to be Presented at the 2021 Military Health System Research Symposium
June 18, 2021
Innovation Pharma Completes Enrollment in Phase 2 Clinical Trial for COVID-19
June 3, 2021
Patient Enrollment Reaches 90 Percent in Innovation Pharmaceuticals Phase 2 Clinical Trial of Brilacidin for COVID-19
May 27, 2021
Innovation Pharma Files Form 10-Q; Patient Enrollment in Phase 2 Clinical Trial of Brilacidin for COVID-19 Tops 70 Percent
May 13, 2021
Innovation Pharma Surpasses 50 Percent Enrollment in Phase 2 Clinical Trial of Brilacidin for COVID-19
April 28, 2021
Innovation Pharma’s Broad Spectrum Antiviral Drug Candidate Brilacidin Highlighted in Biodefense and Infectious Diseases COVID-19 Presentation
April 14, 2021
Innovation Pharma Announces Brilacidin Abstract Accepted for Oral Presentation at the American Society for Virology’s Annual Meeting
April 7, 2021
Innovation Pharma Completes Interim Safety Data Review—DMC Approves Increased Dosing Frequency in Phase 2 Clinical Trial of Brilacidin in Hospitalized COVID-19 Patients
April 5, 2021
Innovation Pharma’s COVID-19 Drug Candidate Brilacidin Ranked in Top Three Percent of Compounds Predicted to Be Most Effective Against SARS-CoV-2
March 10, 2021
Recruitment and Enrollment Underway at Eight Sites for Innovation Pharma’s Phase 2 Clinical Trial of Brilacidin for COVID-19
March 5, 2021
Innovation Pharmaceuticals Announces Publication of Peer-Reviewed Scientific Article in the Journal Viruses on the Anti-SARS-CoV-2 Properties of Brilacidin
March 2, 2021
Innovation Pharma Provides Study Details for Ongoing Phase 2 Clinical Trial of Brilacidin in Hospitalized COVID-19 Patients
February 26, 2021
Innovation Pharmaceuticals’ Phase 2 Clinical Trial of Brilacidin for Treating COVID-19 Scheduled to Begin Next Week
January 29, 2021
Innovation Pharmaceuticals’ Brilacidin for the Treatment of COVID-19 Receives FDA Fast Track Designation
January 14, 2021